首页 | 本学科首页   官方微博 | 高级检索  
     

纳米递送系统线粒体靶向策略在肿瘤诊疗中的应用
引用本文:瞿俊,晏霜,雷龙天洋,欧阳妃君,张海涛,秦旭平. 纳米递送系统线粒体靶向策略在肿瘤诊疗中的应用[J]. 生物化学与生物物理进展, 2024, 51(1): 70-81
作者姓名:瞿俊  晏霜  雷龙天洋  欧阳妃君  张海涛  秦旭平
作者单位:南华大学药学院药物药理研究所,湖南省分子靶标新药研究协同创新中心,南华大学衡阳医学院,衡阳 421001,南华大学药学院药物药理研究所,湖南省分子靶标新药研究协同创新中心,南华大学衡阳医学院,衡阳 421001,南华大学药学院药物药理研究所,湖南省分子靶标新药研究协同创新中心,南华大学衡阳医学院,衡阳 421001,南华大学药学院药物药理研究所,湖南省分子靶标新药研究协同创新中心,南华大学衡阳医学院,衡阳 421001,南华大学药学院药物药理研究所,湖南省分子靶标新药研究协同创新中心,南华大学衡阳医学院,衡阳 421001,南华大学药学院药物药理研究所,湖南省分子靶标新药研究协同创新中心,南华大学衡阳医学院,衡阳 421001
基金项目:湖南省卫生健康委一般指导项目(202113021875),湖南省教育 厅科学研究重点(21A0284),湖南省自然科学基金(2021JJ30603), 湖南省分子靶标新药研究协同创新中心开放基金(0223-0002- 0002000-53) 和南华大学博士科研启动基金(200XQD015) 资助。
摘    要:肿瘤是危害人类健康的重大疾病之一。目前用于肿瘤治疗的方法有手术治疗、化学药物治疗、放射治疗等。然而,传统的治疗方法存在治疗效果不佳、易引发多药耐药、毒副作用大等缺点,仍需进一步探索新的肿瘤治疗靶点和策略。线粒体作为细胞的能量转换器,被认为是肿瘤、心血管和神经性疾病新药设计的最重要靶点之一。纳米药物递送载体具有易被主动靶向基团修饰的特点,可实现细胞乃至细胞器的精准靶向给药。本文从抑制肿瘤细胞增殖、促进肿瘤细胞凋亡、抑制肿瘤复发与转移、诱导细胞自噬等方面综述了线粒体靶向纳米载体在肿瘤诊疗中的应用。

关 键 词:线粒体  靶向治疗  肿瘤治疗  肿瘤诊断  纳米载体
收稿时间:2022-12-30
修稿时间:2023-12-29

Application of Mitochondrial Targeting Strategy of Nano-delivery System in Tumor Diagnosis and Treatment
QU Jun,YAN Shuang,LEI Long-Tian-Yang,OUYANG Fei-Jun,ZHANG Hai-Tao and QIN Xu-Ping. Application of Mitochondrial Targeting Strategy of Nano-delivery System in Tumor Diagnosis and Treatment[J]. Progress In Biochemistry and Biophysics, 2024, 51(1): 70-81
Authors:QU Jun  YAN Shuang  LEI Long-Tian-Yang  OUYANG Fei-Jun  ZHANG Hai-Tao  QIN Xu-Ping
Affiliation:Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China,Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China,Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China,Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China,Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China,Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy and Pharmacology, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China
Abstract:Tumor is one of the major diseases that endanger people’s health. At present, the treatments used for tumor include surgery, chemotherapy, radiotherapy and so on. Nonetheless, the traditional treatments have some disadvantages, such as insufficient treatment effect, liable to cause multidrug resistance, toxicity and side effect. Further research and exploration of tumor treatment schemes are still necessary. As the energy converter of cells, mitochondria are currently considered to be one of the most important targets for the design of new drugs for tumor, cardiovascular and neurological diseases. Nano-drug delivery carriers have the characteristics of being easily modified with active targeting groups, and it can achieve accurate targeted drug delivery to cells and organelles. This paper reviews the application of mitochondrial targeted nanoparticles in tumor diagnosis and treatment from the aspects of inhibiting tumor cell proliferation, promoting tumor cell apoptosis, inhibiting tumor recurrence and metastasis, and inducing cell autophagy.
Keywords:mitochondria  targeted therapy  tumor therapy  tumor diagnosis  nanocarriers
点击此处可从《生物化学与生物物理进展》浏览原始摘要信息
点击此处可从《生物化学与生物物理进展》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号